[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470916":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":68,"centralContacts":72,"locations":78,"responsibleParty":98,"collaborators":67,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":67,"enrollmentInfo":111,"targetDuration":67,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":67,"overallStatus":80,"whyStopped":67,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"University of Miami","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"SMART TNT Plan I","EXPERIMENTAL","Participants will initiate therapy with neoadjuvant chemotherapy of either six (6) 14-day cycles of 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX), six (6) 14-day cycles of 5-fluorouracil + leucovorin + irinotecan + oxaliplatin (mFOLFIRINOX), or four (4) 21-day cycles of capecitabine+oxaliplatin (CAPOX). Participants will then receive chemo-radiation therapy according to Plan I as follows:\n\nPlan I (5 weeks):\n\n* MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.\n* Concurrent chemotherapy beginning on Day 1 of RT either:\n\n  * 5-FU delivered 5 or 7 days per week.\n  * Capecitabine (Xeloda) delivered 5 days per week.\n\nAfter completing Plan I, participants achieving complete Clinical Response (cCR) after completing Plan I chemo-radiation will forgo the Plan II boost and continue to follow-up. Participants not achieving cCR will begin Plan II, one week after completing Plan I.",[13,14,15,16,17,18],"Radiation: Intensity-modulated radiation therapy","Drug: 5-fluorouracil","Drug: Leucovorin","Drug: Oxaliplatin","Drug: Capecitabine","Drug: Irinotecan",{"label":20,"type":10,"description":21,"interventionNames":22},"SMART TNT Plan II","Plan II boost RT (1 week): For participants not achieving cCR after chemo-radiation. Participants will receive MRI-guided accelerated radiation therapy (ART) boost to the primary tumor.\n\nParticipants achieving a cCR will continue to follow-up. Participants still showing residual tumor will undergo standard of care treatment including surgery and adjuvant chemotherapy per institutional guidelines during follow-up.",[23],"Radiation: Accelerated Radiation Therapy",[25,32,39,45,51,57,63],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"RADIATION","Intensity-modulated radiation therapy","MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.",[9],[31],"IMRT",{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","5-fluorouracil","5-FU dose of 400 mg\u002Fm2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg\u002Fm2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.\n\nDuring SMART TNT Plan I, 5-FU dose of 225 mg\u002Fm2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week.",[9],[38],"5-FU",{"type":33,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Leucovorin","Leucovorin dose of 400 mg\u002Fm2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.",[9],[44],"Folinic acid",{"type":33,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"Oxaliplatin","Oxaliplatin dose of 85 mg\u002Fm2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.",[9],[50],"Eloxatin",{"type":33,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"Capecitabine","Capecitabine will be administered orally at a dose of 825 mg\u002Fm2 via tablet twice per day (BID) on Day 1, 5 days per week.",[9],[56],"Xeloda",{"type":26,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Accelerated Radiation Therapy","MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :\n\n* Dose level -1: 10 Gy delivered in 4 fractions\n* Dose level 0: 12 Gy delivered in 4 fractions\n* Dose level 1: 14 Gy delivered in 4 fractions\n* Dose level 2: 16 Gy in delivered 4 fractions",[20],[62],"ART",{"type":33,"name":64,"description":65,"armGroupLabels":66,"otherNames":67},"Irinotecan","Irinotecan dose of 180 mg\u002Fm2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.",[9],null,[69],{"name":70,"affiliation":5,"role":71},"Benjamin Spieler, MD","PRINCIPAL_INVESTIGATOR",[73],{"name":74,"role":75,"phone":76,"phoneExt":67,"email":77},"Zuzel Rodriguez","CONTACT","305-243-0124","z.rodriguez1@med.miami.edu",[79],{"facility":5,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"RECRUITING","Miami","Florida","33136","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-80.19366,25.77427,{"lat":90,"lon":89},[93,94,97],{"name":74,"role":75,"phone":76,"phoneExt":67,"email":77},{"name":70,"role":75,"phone":95,"phoneExt":67,"email":96},"305-243-4229","bspieler@miami.edu",{"name":70,"role":71,"phone":67,"phoneExt":67,"email":67},{"type":71,"investigatorFullName":99,"investigatorTitle":100,"investigatorAffiliation":5,"oldNameTitle":67,"oldOrganization":67},"Benjamin Spieler","Assistant Professor of Clinical","100470916","phase-1-smart-tnt-for-the-conservative-management-of-locally-advanced-rectal-cancer-100470916",false,"NCT05412082","SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","Selective Treatment With Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined With Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer","SMART TNT","Inclusion Criteria:\n\n1. Patients with newly diagnosed, biopsy proven, rectal adenocarcinoma.\n2. Primary tumor located ≤18 cm from margin verge.\n3. Primary tumor either a T3N0 or T1-4 N positive (as defined per pelvic MRI; nodes ≤ 15 mm).\n4. ≥ 18 years of age.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n6. Serum liver function tests values within the range of 1.5 x Upper Limit of Normal (within 6 weeks of enrollment).\n7. Negative pregnancy test for women of child-bearing potential (within 4 weeks of enrollment).\n8. Ability to understand and the willingness to sign a written informed consent document.\n9. Patient is assessed by a surgeon, medical oncologist and a radiation oncologist and deemed fit for Total Neoadjuvant ChemoTherapy (TNT) and surgery.\n\nExclusion Criteria:\n\n1. Metastatic disease on initial work up (Chest and abdomen contrast enhanced CT scan).\n2. Synchronous cancer found on colonoscopy.\n3. Previous history of pelvic radiotherapy.\n4. History of concurrent, active malignancy other than non-metastatic skin cancer within the last 2 years.\n5. Symptomatic congestive heart failure of New York Heart Association Class III or IV, unstable angina pectoris or uncontrolled severe cardiac arrhythmia, myocardial infarction within the last 6 months.\n6. Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n7. Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics or active tuberculosis (TB).\n8. Patients with poorly controlled acquired immune deficiency syndrome (AIDS) who are not deemed candidates for FOLFOX, mFOLFIRINOX or CAPOX chemotherapy. Active connective tissue disorders, such as lupus or scleroderma, that, in the opinion of the treating physician may put the patient at high risk for radiation toxicity.\n9. Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity\n10. Sensory or motor neuropathy ≥ grade 2.\n11. Women who are breast feeding.\n12. Exclusions due to MRI use in study: ferromagnetic metal in body\u002Feye, pacemaker, defibrillator, other mechanical device, or extreme claustrophobia (medication with anti-anxiety agents, such as Ativan, may be attempted).","ALL","18 Years",{"count":112,"type":113},25,"ESTIMATED","INTERVENTIONAL",[116],"PHASE1","The purpose of this research study is to find out how safe and effective is treating patients with locally advanced rectal cancer (LARC) with chemotherapy first and then follow with radiation therapy to a higher dose than what is usually delivered and see if patients could have complete response and be spared from surgery.",[119],"Locally Advanced Rectal Cancer","2026-02-04",{"date":122,"type":123},"2026-02-06","ACTUAL",{"date":125,"type":123},"2022-10-05",{"date":127,"type":113},"2028-10-31",{"name":5,"class":6},1]